Cargando…

Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity

Purpose. To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injec...

Descripción completa

Detalles Bibliográficos
Autores principales: El Matri, Leila, Bouraoui, Rym, Chebil, Ahmed, Kort, Fedra, Bouladi, Mejda, Limaiem, Rym, Landoulsi, Hana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228294/
https://www.ncbi.nlm.nih.gov/pubmed/22174999
http://dx.doi.org/10.1155/2012/861384
_version_ 1782217807746826240
author El Matri, Leila
Bouraoui, Rym
Chebil, Ahmed
Kort, Fedra
Bouladi, Mejda
Limaiem, Rym
Landoulsi, Hana
author_facet El Matri, Leila
Bouraoui, Rym
Chebil, Ahmed
Kort, Fedra
Bouladi, Mejda
Limaiem, Rym
Landoulsi, Hana
author_sort El Matri, Leila
collection PubMed
description Purpose. To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injection. Results. Mean followup was 14.1 months ±  7.1 (range: 5 to 24 months). Mean logMAR vision at baseline was 1.38 logMAR ±  0.33, at 6 months was 1.14 logMAR ±  0.37 (P = 0.001) and at 12 months was 1.22 logMar ±  0.33 (P = 0.004). Mean baseline central retinal thickness was 431 μm ±  159.7 at 6 months was 293.43 μm  ±  122.79 (P = 10(−4)) and at 12 months was 293.1 μm  ±  130 (P = 0.004). Visual acuity improved in both patients with or without prior PDT treatment. Conclusions. Intravitreal bevacizumab injection may increase the chance of visual acuity gain in neovascular AMD even in cases with initial low visual acuity.
format Online
Article
Text
id pubmed-3228294
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32282942011-12-15 Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity El Matri, Leila Bouraoui, Rym Chebil, Ahmed Kort, Fedra Bouladi, Mejda Limaiem, Rym Landoulsi, Hana J Ophthalmol Clinical Study Purpose. To evaluate functional and anatomic effects of intravitreal bevacizumab in patients with neovascular AMD and initial low visual acuity. Methods. Retrospective case series of 38 eyes with neovascular AMD and initial visual acuity of 20/200 or less, treated with intravitreal bevacizumab injection. Results. Mean followup was 14.1 months ±  7.1 (range: 5 to 24 months). Mean logMAR vision at baseline was 1.38 logMAR ±  0.33, at 6 months was 1.14 logMAR ±  0.37 (P = 0.001) and at 12 months was 1.22 logMar ±  0.33 (P = 0.004). Mean baseline central retinal thickness was 431 μm ±  159.7 at 6 months was 293.43 μm  ±  122.79 (P = 10(−4)) and at 12 months was 293.1 μm  ±  130 (P = 0.004). Visual acuity improved in both patients with or without prior PDT treatment. Conclusions. Intravitreal bevacizumab injection may increase the chance of visual acuity gain in neovascular AMD even in cases with initial low visual acuity. Hindawi Publishing Corporation 2012 2011-11-29 /pmc/articles/PMC3228294/ /pubmed/22174999 http://dx.doi.org/10.1155/2012/861384 Text en Copyright © 2012 Leila El Matri et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
El Matri, Leila
Bouraoui, Rym
Chebil, Ahmed
Kort, Fedra
Bouladi, Mejda
Limaiem, Rym
Landoulsi, Hana
Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
title Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
title_full Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
title_fullStr Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
title_full_unstemmed Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
title_short Bevacizumab Injection in Patients with Age-Related Macular Degeneration Associated with Poor Initial Visual Acuity
title_sort bevacizumab injection in patients with age-related macular degeneration associated with poor initial visual acuity
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228294/
https://www.ncbi.nlm.nih.gov/pubmed/22174999
http://dx.doi.org/10.1155/2012/861384
work_keys_str_mv AT elmatrileila bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity
AT bouraouirym bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity
AT chebilahmed bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity
AT kortfedra bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity
AT bouladimejda bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity
AT limaiemrym bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity
AT landoulsihana bevacizumabinjectioninpatientswithagerelatedmaculardegenerationassociatedwithpoorinitialvisualacuity